Neglected Tropical Diseases Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The neglected tropical diseases market was valued at USD 3.18 Billion in 2025 and is expected to grow at a CAGR of 3.90%, reaching USD 4.66 Billion by 2035. The market growth is driven by increasing funding for research and public-private partnerships combating neglected tropical diseases. The growing adoption of novel therapeutics and diagnostics is expanding treatment access. The emphasis on integrated disease management programs is improving patient outcomes. The expansion into underserved regions will fuel value growth through enhanced screening, prevention initiatives, and broader healthcare infrastructure investment.

Key Market Trends and Insights

• Based on disease type, the buruli ulcer segment held nearly 11% of market share in the historical period.
• By drug class, the antibiotic agents’ segment is expected to lead the market in the forecast period.
• Based on route of administration, the oral segment is expected to dominate the market in the forecast period.

Market Size and Forecast

• Market Size (2025): USD 3.18 Billion
• Projected Market Size (2035): USD 4.66 Billion
• CAGR (2026-2035): 3.90%

Neglected Tropical Diseases Market Overview

Neglected tropical diseases represent a group of chronic, infectious conditions that predominantly affect low-income populations in tropical and subtropical regions, contributing to long-term disability, reduced productivity, and significant public health burdens worldwide. The market focuses on prevention, diagnosis, and treatment solutions driven by increasing government initiatives, international funding, and rising awareness programs. The market was valued at USD 3.18 Billion in 2025. The growth is supported by expanding access to healthcare, improved drug development, and strategic collaborations aimed at disease control. Overall, the market is expected to maintain steady expansion globally.

Neglected Tropical Diseases Market Growth Driver

Increasing Strategic Disease Elimination Initiatives Driving the Market Development

The accelerated elimination of key neglected tropical diseases has emerged as a significant driver for market expansion. In October 2024, the World Health Organization declared India free of Trachoma as a public health problem, marking it as the third country in the Southeast Asia region to achieve this milestone. This success followed the implementation of comprehensive disease management strategies, including the WHO SAFE strategy, continuous surveillance, and robust public health interventions. Additionally, India’s targeted efforts in malaria control have reduced disease burden significantly. These initiatives highlight improved healthcare infrastructure, hygiene practices, and effective disease monitoring, collectively fueling growth in the neglected tropical diseases market.

Neglected Tropical Diseases Market Trends

The market is experiencing key trends, including the expansion of access to rare disease vaccines and the growing development of indigenous dengue vaccines.

Expansion of Rare Disease Vaccine Access is Likely to Enhance the Market Growth

The market is witnessing a notable trend in enhanced vaccine accessibility and strategic marketing authorization transfers. In October 2024, OrphanPacific, Inc. assumed marketing authorization for Rabipur Intramuscular Injection in Japan, previously held by GlaxoSmithKline Co., Ltd., strengthening pre- and post-exposure rabies prevention. Rabipur remains the only approved rabies vaccine in Japan, addressing critical gaps in prophylaxis for a nearly 100% fatal disease once symptoms appear. Such initiatives, reflecting increased focus on rare and imported infectious diseases, are expected to drive market expansion, improve patient outcomes, and bolster investment in vaccine development for NTDs.

Rising Indigenous Dengue Vaccine Development to Boost the Neglected Tropical Diseases Market Value

The development of India’s first indigenous dengue vaccine, DengiAll, signifies a pivotal advancement in addressing neglected tropical diseases. In August 2024, the Indian Council of Medical Research (ICMR) and Panacea Biotec initiated the Phase 3 clinical trial of DengiAll across 19 sites in 18 States and Union Territories, enrolling over 10,335 participants. This collaboration highlights India’s growing capabilities in vaccine research and aligns with national health priorities. The introduction of an effective dengue vaccine is expected to enhance disease prevention strategies and stimulate innovation in the neglected tropical diseases market, thereby supporting sustained market growth globally.

Neglected Tropical Diseases Market Share

Buruli Ulcer Segment Expected to Drive the Market Based on the Type of Diseases

The market is segmented into schistosomiasis, lymphatic filariasis (elephantiasis), trachoma, leprosy, dengue, Chagas disease, rabies, Buruli ulcer, soil-transmitted helminths (STHs), and others. Among these, the Buruli ulcer segment is expected to lead the market, having held nearly 11% share during the historical period. Its strong position is supported by rising diagnosis rates, growing awareness programs, and increasing focus on early treatment to prevent severe complications. Continued public health initiatives and improved access to therapies are anticipated to further strengthen the segment’s contribution to overall market growth.

Neglected Tropical Diseases Market Analysis by Region

The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is emerging as a leading region due to concerted efforts in disease surveillance, research, and awareness programs. Notably, in November 2025, the Pan American Health Organization (PAHO) and the Ministry of Health in Guyana launched the 2025 Mass Drug Administration (MDA) campaign, targeting Lymphatic Filariasis and other NTDs. This initiative underscores the critical role of coordinated national and regional strategies in disease elimination, enhanced community engagement, and the implementation of effective treatment regimens, reinforcing the United States’ leadership in NTD management.

Leading Players in the Neglected Tropical Diseases Market

The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by leading players. The major companies in the market are as follows:

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. plays a significant role in addressing neglected tropical diseases through sustained research, product development, and global health partnerships. The company has developed anti-malarial therapies such as Lariam and Fansidar and supported innovative treatments through collaborations, including malaria and diarrheal disease research initiatives. Roche also transferred manufacturing rights for Benzonidazole to support Chagas disease treatment and expanded access to essential diagnostics in underserved regions. Its compound library and employee programs further strengthen contributions to neglected disease research and care.

Bayer AG

Bayer AG is actively involved in addressing Neglected Tropical Diseases, particularly vector-borne illnesses such as malaria, dengue, kala-azar, chikungunya, filariasis, and Japanese encephalitis. The company focuses on innovative vector control solutions, including advanced insecticides and treatment kits, to combat disease transmission and resistance challenges. Through public-private partnerships, community education programs, and collaborations with institutions such as Banaras Hindu University, Bayer supports large-scale disease prevention and elimination efforts. Its initiatives align with global sustainable development goals, reinforcing its commitment to reducing disease burden by 2030.

Sanofi S.A.

Sanofi S.A., through its philanthropic arm Foundation S - The Sanofi Collective, actively contributes to the neglected tropical diseases market by supporting initiatives aimed at eliminating sleeping sickness. Since its launch in 2022, Foundation S has driven collective action to improve access to medicines, strengthen community health systems, and empower healthcare workers. Its recent programs focus on climate resilience and health equity, positively impacting millions of people globally. The foundation plays a significant role in advancing disease elimination efforts while enhancing healthcare infrastructure in vulnerable regions.

Pfizer Inc.

Pfizer Inc. plays a significant role in the market through its longstanding partnership with the International Trachoma Initiative to support global trachoma elimination efforts. Since 1998, the company has donated over one billion doses of its antibiotic, supporting the World Health Organization-recommended S.A.F.E. strategy, which includes surgery, antibiotic treatment, facial cleanliness, and environmental improvements. This initiative has reached more than 300 million people across over 40 countries, contributing to a substantial reduction in the global burden of trachoma and strengthening public health systems worldwide.

Other key players in the market include Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, AstraZeneca plc, Eisai Co. Ltd., and Astellas Pharma.

Neglected Tropical Diseases Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type of Diseases

• Schistosomiasis
• Lymphatic Filariasis (Elephantiasis)
• Trachoma
• Leprosy
• Dengue
• Chagas Disease
• Rabies
• Buruli Ulcer
• Soil-Transmitted Helminths (STHs)
• Other

Market Breakup by Drug Class

• Antiparasitic Agents
• Anthelmintics
• Antiprotozoals
• Antifilarials
• Antibiotic Agents
• Vaccines
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Topical

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Key Questions Answered in the Neglected Tropical Diseases Market Report

• What was the neglected tropical diseases market value in 2025?
• What is the neglected tropical diseases market forecast outlook for 2026-2035?
• What are the major factors aiding the neglected tropical diseases market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major neglected tropical diseases market trends?
• Which type of disease is expected to dominate the market segment?
• Which drug class is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players involved in the neglected tropical diseases market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?